Log in

NASDAQ:XON - Intrexon Stock Price, Forecast & News

$5.37
+0.01 (+0.19 %)
(As of 12/9/2019 06:43 AM ET)
Today's Range
$5.30
Now: $5.37
$5.47
50-Day Range
$5.04
MA: $5.45
$6.03
52-Week Range
$3.95
Now: $5.37
$9.68
Volume653,757 shs
Average Volume1.10 million shs
Market Capitalization$873.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XON
CUSIPN/A
Phone301-556-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$160.57 million
Book Value$2.76 per share

Profitability

Net Income$-509,340,000.00
Net Margins-393.13%

Miscellaneous

EmployeesN/A
Market Cap$873.59 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive XON News and Ratings via Email

Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter.


Intrexon (NASDAQ:XON) Frequently Asked Questions

What is Intrexon's stock symbol?

Intrexon trades on the NASDAQ under the ticker symbol "XON."

How were Intrexon's earnings last quarter?

Intrexon Corp (NASDAQ:XON) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.05. The biotechnology company earned $35.99 million during the quarter, compared to analysts' expectations of $29.62 million. Intrexon had a negative return on equity of 45.51% and a negative net margin of 393.13%. The company's revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.51) EPS. View Intrexon's Earnings History.

When is Intrexon's next earnings date?

Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intrexon.

What price target have analysts set for XON?

3 equities research analysts have issued 1-year price targets for Intrexon's shares. Their forecasts range from $6.00 to $43.00. On average, they expect Intrexon's share price to reach $19.67 in the next year. This suggests a possible upside of 266.2% from the stock's current price. View Analyst Price Targets for Intrexon.

What is the consensus analysts' recommendation for Intrexon?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon.

What are Wall Street analysts saying about Intrexon stock?

Here are some recent quotes from research analysts about Intrexon stock:
  • 1. Northland Securities analysts commented, "We believe the company will spin-off its assets as the company has backed away from its target cash burn goal of $70M." (8/12/2019)
  • 2. According to Zacks Investment Research, "We are positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations and joint ventures. Intrexon's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates in partnership deals, targeting a broad range of diseases including cancer. Additionally, the company announced the formation of a wholly-owned subsidiary, Precigen, Inc. as part of its structural alternatives, so that it can take better decisions regarding its health business. However, the company largely depends on ECCs and license, and collaboration deals for revenues. Any unfavorable outcome from the development of these might be a major setback and hurt the company’s prospects too. Though, estimates have remained stable ahead of its Q4 earnings release, Intrexon has a positive record of earnings surprises in recent quarters." (1/26/2019)

Has Intrexon been receiving favorable news coverage?

News articles about XON stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intrexon earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Intrexon.

Who are some of Intrexon's key competitors?

What other stocks do shareholders of Intrexon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Alibaba Group (BABA) and General Electric (GE).

Who are Intrexon's key executives?

Intrexon's management team includes the folowing people:
  • Mr. Randal J. Kirk, Chairman & CEO (Age 65)
  • Mr. Rick L. Sterling, Chief Financial Officer (Age 54)
  • Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)
  • Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46)

Who are Intrexon's major shareholders?

Intrexon's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.69%), Nikko Asset Management Americas Inc. (1.97%), Sumitomo Mitsui Trust Holdings Inc. (1.97%), Wellington Shields Capital Management LLC (0.15%), Millennium Management LLC (0.10%) and Lagoda Investment Management L.P. (0.08%). Company insiders that own Intrexon stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Institutional Ownership Trends for Intrexon.

Which institutional investors are selling Intrexon stock?

XON stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, NJ State Employees Deferred Compensation Plan and Stephens Inc. AR. Company insiders that have sold Intrexon company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Insider Buying and Selling for Intrexon.

Which institutional investors are buying Intrexon stock?

XON stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Millennium Management LLC, First Trust Advisors LP, CWM LLC, SG Americas Securities LLC, California Public Employees Retirement System and Virtu Financial LLC. View Insider Buying and Selling for Intrexon.

How do I buy shares of Intrexon?

Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intrexon's stock price today?

One share of XON stock can currently be purchased for approximately $5.37.

How big of a company is Intrexon?

Intrexon has a market capitalization of $873.59 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. View Additional Information About Intrexon.

What is Intrexon's official website?

The official website for Intrexon is http://www.dna.com/.

How can I contact Intrexon?

Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]


MarketBeat Community Rating for Intrexon (NASDAQ XON)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  351 (Vote Underperform)
Total Votes:  727
MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel